ArticlePediatric nephrology (Berlin, Germany)2026
Impact of post-filter ionized calcium target range on circuit survival and citrate-related complications in pediatric continuous kidney replacement therapy.
Article in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRegional citrate anticoagulation (RCA) is the preferred strategy for continuous kidney replacement therapy in children; however, the optimal post-filter ionized calcium target remains uncertain. Lower targets may increase anticoagulation but raise citrate exposure and metabolic complications. We aimed to compare anticoagulation efficacy and metabolic safety between a low-target (0.25-0.35 mmol/L) and a high-target (0.30-0.40 mmol/L) post-filter ionized calcium protocol in critically ill children.
methodsThis retrospective cohort study included critically ill children receiving continuous veno-venous hemodiafiltration with citrate as the pre-filter anticoagulation solution at a tertiary pediatric intensive care unit over a 4-year period. A total of 87 patients (42 low-target, 45 high-target) and 154 circuits (71 versus 83) were analyzed. The primary outcome was circuit survival (CS). Secondary outcomes included citrate dose, citrate load, and RCA-related complications. Continuous variables were analyzed using the Mann-Whitney U test, and CS was assessed with Cox regression. Linear mixed models evaluated citrate changes, and generalized estimating equations analyzed metabolic outcomes.
resultsMedian CS was comparable between groups (49 versus 48 h, p = 0.76) as was the survival of clotted circuits (41 versus 40 h, p = 0.70) and circuit clotting rates were similar (21.1% versus 24.1%, p = 0.70). The low-target group had higher median citrate dose (2.9 versus 2.6 mmol/L, p < 0.001), citrate load (0.76 versus 0.72 mmol/kg/h, p = 0.03), and more frequent hypocalcemia (17.5% versus 12.9%, p = 0.01), metabolic alkalosis (31.9% versus 22.8%, p < 0.001), and citrate accumulation (24.5% versus 15.4%, p < 0.001). Linear mixed models showed a persistently higher citrate dose and citrate load in the low-target group (all p < 0.001). Generalized estimating equations demonstrated increased odds of hypocalcemia (odds ratio 1.47, p = 0.01) and citrate accumulation (odds ratio 1.93, p < 0.001) in the low-target group.
conclusionsRaising the target of post-filter ionized calcium from 0.25-0.35 to 0.30-0.40 mmol/L reduced citrate exposure and metabolic complications without compromising CS.
trial registrationRetrospectively registered.
Indexed as
Identifiers
42418001What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.